David Colleran's most recent trade in Anika Therapeutics Inc. was a trade of 28,165 Restricted Stock Unit done . Disclosure was reported to the exchange on March 14, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 28,165 | 28,165 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 13,669 | 13,669 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 6,448 | 12,897 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 6,448 | 49,847 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.91 per share. | 14 Mar 2025 | 1,893 | 47,954 (0%) | 0% | 15.9 | 30,118 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 7,663 | 0 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2025 | 7,663 | 45,649 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.79 per share. | 11 Mar 2025 | 2,250 | 43,399 (0%) | 0% | 16.8 | 37,778 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,465 | 39,590 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,465 | 5,465 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.62 per share. | 10 Mar 2025 | 1,604 | 37,986 (0%) | 0% | 16.6 | 26,658 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 46,875 | 46,875 | - | - | Stock Option (Right to Buy) | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 19,345 | 19,345 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 7,662 | 35,245 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 7,662 | 7,663 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,465 | 10,930 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,465 | 29,188 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,682 | 0 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 3,682 | 24,804 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.79 per share. | 11 Mar 2024 | 2,250 | 32,995 (0%) | 0% | 25.8 | 58,028 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,605 | 27,583 (0%) | 0% | 25.4 | 40,799 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.42 per share. | 11 Mar 2024 | 1,081 | 23,723 (0%) | 0% | 25.4 | 27,479 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,663 | 15,325 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,663 | 22,538 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 10 Mar 2023 | 2,250 | 20,288 (0%) | 0% | 26.1 | 58,725 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 35,790 | 35,790 | - | - | Stock Option (Right to Buy) | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 16,395 | 16,395 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 3,683 | 3,682 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 3,683 | 15,956 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.91 per share. | 09 Mar 2023 | 1,081 | 14,875 (0%) | 0% | 26.9 | 29,090 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2023 | 2,500 | 13,007 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2023 | 2,500 | 0 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.59 per share. | 04 Mar 2023 | 734 | 12,273 (0%) | 0% | 31.6 | 23,187 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Purchase of securities on an exchange or from another person at price $ 21.37 per share. | 11 May 2022 | 1,500 | 9,867 (0%) | 0% | 21.4 | 32,055 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Purchase of securities on an exchange or from another person at price $ 26.65 per share. | 14 Mar 2022 | 1,500 | 8,367 (0%) | 0% | 26.7 | 39,978 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 35,864 | 35,864 | - | - | Stock Option (Right to Buy) | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 22,988 | 22,988 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 3,682 | 7,365 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 3,682 | 7,948 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.22 per share. | 09 Mar 2022 | 1,081 | 6,867 (0%) | 0% | 26.2 | 28,344 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 2,500 | 5,000 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.06 per share. | 04 Mar 2022 | 734 | 4,266 (0%) | 0% | 31.1 | 22,798 | Common Stock |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 27,681 | 27,681 | - | - | Stock Option (Right to Buy) | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 11,047 | 11,047 | - | - | Restricted Stock Unit | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 2,500 | 2,500 (0%) | 0% | 0 | Common Stock | |
Anika Therapeutics Inc. | David Colleran | EVP, General Counsel, Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit |